StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)

Stock analysts at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report issued on Sunday. The firm set a “sell” rating on the medical technology company’s stock.

Several other equities research analysts have also commented on the company. Ascendiant Capital Markets decreased their price target on BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. Benchmark reiterated a “speculative buy” rating and set a $0.40 target price on shares of BIOLASE in a research report on Wednesday, October 2nd.

BIOLASE Stock Up 1.4 %

Shares of NASDAQ BIOL opened at $0.01 on Friday. The stock has a market capitalization of $250,552.50, a price-to-earnings ratio of 0.00 and a beta of 0.67. BIOLASE has a 52 week low of $0.02 and a 52 week high of $1.94. The firm has a 50-day moving average price of $0.01 and a 200 day moving average price of $0.05.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.